Who has been buying ST Pharm stock?

2 distinct insiders have filed 1 disclosed insider purchases in ST Pharm (237690), most recently on 2026-04-24. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does ST Pharm have?

ST Pharm has 1 buy-side and 1 sell-side disclosures on record, covering ₩620M ($431K) in total reported value, spanning 2024-06-19 to 2026-04-24.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

ST Pharm 237690

Company

에스티팜ST Pharm

Insiders

Buys

Total Value

₩620M ($431K)

Avg Return

+51.16%

Last Filing

2026-04-24

ST Pharm (237690) has 1 disclosed insider purchases and 1 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩620M ($431K) in reported transaction value. The earliest filing StockDrifts holds for ST Pharm is dated 2024-06-19; the most recent is 2026-04-24. Across these filings the average return since disclosure is +51.16%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-07-31	BUY	Market Buy	최용훈 Yonghoon Choi	Planning Director	350	₩88,500	+0.0%	₩35M ($25K)
2026-04-24	BUY	주식매수선택권	최석우 Seokwoo Choi	Managing Director	5.0K	₩148,000	+3.0%	₩740M ($514K)
2026-04-24	BUY	주식매수선택권	임진석 Lim Jin-seok	Gyeongsan Factory Manager	5.0K	₩148,000	+3.0%	₩740M ($514K)
2026-04-03	BUY	주식매수선택권	윤정열 Yoon Jeong-yeol	Director of Quality Management Division	4.7K	₩138,100	+0.7%	₩642M ($446K)
2026-03-30	SELL	Market Sell	임진석 Lim Jin-seok	Gyeongsan Factory Manager	-3.6K	₩148,800	+6.6%	₩543M ($377K)
2026-03-27	SELL	임원퇴임	김이환 Lee Hwan Kim	Planning Director	-1.0K	₩159,300	+12.7%	₩159M ($111K)
2026-03-19	BUY	주식매수청구권 행사	임진석 Lim Jin-seok	Gyeongsan Factory Manager	3.6K	₩149,500	-7.0%	₩546M ($379K)
2025-03-18	BUY	Market Buy	김이환 Lee Hwan Kim	Head of Management Planning Department	1.0K	₩77,200	+95.7%	₩77M ($54K)
2024-08-20	SELL	시간외매매	강정석 Jeongseok Kang	-	-950.0K	₩98,500	-53.4%	₩93.6B ($65.0M)
2024-06-19	SELL	임원퇴임	김경진 Kyungjin Kim	CEO and President	-100	₩92,300	-63.7%	₩9M ($6K)

Frequently asked questions

Who has been buying ST Pharm stock?: 2 distinct insiders have filed 1 disclosed insider purchases in ST Pharm (237690), most recently on 2026-04-24. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does ST Pharm have?: ST Pharm has 1 buy-side and 1 sell-side disclosures on record, covering ₩620M ($431K) in total reported value, spanning 2024-06-19 to 2026-04-24.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.